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After the 2012 Nobel Prize in Chemistry was awarded for 
the study of G-protein-coupled receptors (GPCRs), renewed 
interest was evident within the field. As seven-transmem- 
brane (7TM) receptors with crucial physiological and 
pathological functions, GPCRs are the most popular drug 
targets known. In recent years, the Chinese government has 
funded several major projects on basic GPCR research and 
new drug discovery research targeting GPCRs through the 
National Basic Research Program (973 Program) and Na-
tional Scientific and Technological Major Project for “Sig-
nificant New Drugs Creation and Manufacturing Program”. 
With the support from 973 Program (2012CB910400), Dr. 
Zhao Qiang’s group from the Shanghai Institute of Materia 
Medica reported the high resolution (2.7 Å) crystal structure 
of P2Y12R in complex with a non-nucleotide reversible an-
tagonist, AZD1283, in Nature [1]. Their findings provide 
the ground work for P2Y12R- based drug research and de-
velopment.  
Purinergic P2Y receptors which belong to the group of 
metabotropic P2Y purinergic GPCRs stimulated by nucleo-
tides, play crucial roles in inflammation, cancer and cardio-
vascular diseases. There are two distinct P2Y receptors for 
ADP expressed on platelets: the Gq-coupled P2Y1R and the 
Gi-coupled P2Y12R. Both contribute to collagen-induced 
platelet microparticle formation in whole blood and the 
formation of platelet-leukocyte aggregates. However, only 
P2Y12R is involved in the exposure of phosphatidylserine 
by thrombin or other platelet agonists [2]. P2Y12R (formerly 
SP1999) was discovered and identified as an ADP receptor 
with platelet clopidogrel sensitivity in 2001 [3]. Several 
generations of P2Y12R-targeted antithrombotic drugs have 
been developed because of its critical functional role in 
platelet aggregation. The first generation drugs, such as 
ticlopidine, clopidogrel and prasugrel, were prodrugs which 
needed to be metabolized before covalently binding to 
P2Y12R. Now newer drugs including ticagrelor, cangrelor 
and elinogrel that are either approved by the FDA or are 
still in clinical trials, directly act on P2Y12R. However, 
clinical studies have revealed certain limitations of these 
drugs including their long half-life and/or significant side 
effects. There is an unfulfilled medical need to develop new 
generation P2Y12R inhibitors, which was previously se-
verely limited because of a lack of receptor structural and 
biochemical information. 
Dr. Zhao’s group modified the protein sequence of the 
P2Y12R by inserting the thermostabilized apocytochrome 
b562RIL (BRIL) into the third intracellular loop region of the 
receptor, and incorporating a D2947.49N (superscript Balles-
teros-Weinstein nomenclature) mutation in the N[D]P7.50xxY 
motif of the seventh transmembrane region to improve the 
protein yield and facilitate crystallization. The crystal 
structure of the antagonist AZD1283 (a novel P2Y12R an-
tagonist developed for inhibition of artery thrombosis by 
AstraZeneca) bound to P2Y12R was solved for a crystal with 
C2 space group.  
The P2Y12R structure contains the typical seven trans-
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membrane helices (as shown in Figure 1). Helix VIII in the 
C-terminal part is well resolved and is parallel to the lipid 
bilayer. The only observed disulfide bond is formed be-
tween C17 in the N-terminal part and C2707.25, while the 
conserved disulfide bond between C973.25 and C175ECL2 is 
flexible and thus, was not modeled [4]. Two cholesterol 
molecules bound to each receptor are observed, suggesting 
the potential role of cholesterol in P2Y12R mediated signal 
transduction. When compared with those of other known 
GPCRs, the structures of the V and VI transmembrane heli-
ces are significantly different in P2Y12R [5]. 
The AZD1283 binding pocket is composed of residues 
from helix III to helix VII. This pocket was previously only 
found in the GPCR PAR1. As both receptors (P2Y12R and 
PAR1) belong to the δ subgroup of GPCRs, this binding 
pocket may contain features that are common within the δ 
subgroup of GPCRs. A series of amino acid side chains in 
the helices are involved in polar and hydrophobic interac-  
 
 
Figure 1  Overview of the P2Y12R-AZD1283 complex structure and 
ligand-binding for AZD1283. A, Cartoon representation of P2Y12R. 
P2Y12R is shown as a green ribbon. AZD1283 is shown as magenta spheres. 
Cholesterol and lipids are yellow carbon stick structures. B, Views of 
P2Y12R (green) compared with β2AR (PDB accession 2RH1, brown) and 
PAR1 (PDB accession 3VW7, blue). C, Key residues in P2Y12R for 
AZD1283 binding. AZD1283 (gray carbons) and receptor residues (yellow 
carbons) involved in ligand binding are shown as stick structures. D, The 
two pocket binding model of P2Y12R. The ligand AZD1283 and docking 
pose of the active metabolite of clopidogrel are shown as green carbon 
stick structures. 
tions with the ligand. The benzene ring of Y1053.33 interacts 
with the nicotinate of AZD1283 via a π-π interaction, while 
it has a hydrophobic interaction with the piperidine group. 
The phenyl group of AZD1283 is accommodated by the 
hydrophobic pocket formed by F2526.51, R2566.55, Y2596.58, 
L2767.31 and K2807.35. 
Besides the AZD1283 binding site, there is another 
binding pocket observed in the crystal structure of P2Y12R, 
which is composed of helices I-III and VII. This is the first 
time that two different extracellular binding sites have been 
observed in a GPCR structure. Docking assays suggest that 
the AZD1283 binding pocket interacts with reversible lig-
ands, while the other pocket may favor covalent small mol-
ecules. This indicates that an allosteric modification mecha- 
nism may play a role in regulating P2Y12R signaling. Ac-
cording to the docking analysis, C973.25, which is thought to 
form a conserved disulfide bond with C175ECL2, is probably 
the covalent binding site of an active metabolite. This cor-
relates well with the labile disulfide bond observed in the 
structure of P2Y12R; the active metabolites are reactive thi-
ols, which would react with free cysteines rather than disul-
fides in the receptor. As P2Y12R is an important drug de-
velopment target, its structure provides valuable insights for 
the development of improved P2Y12R antagonists. The 
unique conformation of the P2Y12R structure deepens our 
understanding of the ligand recognition elements of the pu-
rinergic receptor and the biological functions of GPCRs. 
Future structural studies of P2Y12R that build on the infor-
mation described herein will support the design of new 
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